Prime Highlights :
- UPS posted its first-ever $3 billion healthcare revenue quarter this year, with its healthcare portfolio gaining market share every year since 2021.
- DHL Supply Chain said it plans to invest around $2.25 billion in health logistics by 2030, with half allocated to the Americas.
Key Facts :
- GLP-1 medications, including popular weight-loss and diabetes drugs, require refrigerated storage and precise delivery windows to remain effective.
- FedEx recently launched a dedicated life sciences unit, with healthcare transportation revenue reaching nearly $10 billion in its last fiscal year.
Background :
Logistics companies including UPS and FedEx are strengthening their cold-chain capabilities as demand grows for temperature-sensitive medications such as GLP-1 drugs used for weight loss and diabetes. Most injectable GLP-1 treatments require refrigerated storage throughout shipment, adding pressure on supply chains already stretched by rising demand.
UPS said in June it would invest $48 million in temperature-controlled facilities to meet growing demand for critical treatments. The company’s healthcare portfolio has gained market share every year since 2021, and it posted its first-ever $3 billion healthcare revenue quarter earlier this year. UPS executives said the biggest challenge lies in the narrow margin for error, as even brief temperature deviations can damage medicines.
FedEx recently launched a dedicated life sciences unit to support pharmaceutical transportation, with healthcare revenue reaching close to $10 billion in its last fiscal year. The company said it is investing in predictive technology to track products and expand cold-chain infrastructure.
C.H. Robinson reported surpassing $1 billion in healthcare logistics revenue over the past year, driven largely by GLP-1 growth, while DHL Supply Chain said it plans to invest around $2.25 billion in health logistics by 2030. DHL has also launched a dedicated pharmaceutical air corridor to maintain consistent regulatory and temperature conditions during transit.
Industry figures said refrigerated supply capacity remains limited even as demand rises, prompting continued investment across the sector. A recent Gallup poll found that eleven percent of Americans now use GLP-1 medications for weight loss, up sharply from a few years earlier.
